Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05570305 · ClinicalTrials.gov registry record · Phase 2
Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
A Phase 2 study, sponsored by University Medical Center Groningen.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT05570305 is a Phase 2 study that has completed, run by University Medical Center Groningen. The registered enrollment target is 42 participants.
The verdict
NCT05570305, a Phase 2 study, has completed, sponsored by University Medical Center Groningen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid retaining effects of zibotentan can be mitigated by dapagliflozin.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
- DRUG Zibotentan
- DRUG Dapagliflozin and Zibotentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2025-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05570305
The ClinicalTrials.gov registry entry for NCT05570305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Medical Center Groningen, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05570305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05570305 about?
NCT05570305 is a clinical study titled "Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria". The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid retaining effects of zibotentan can be mitigated by dapagliflozin.
What is the current status of trial NCT05570305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2022-10-06. Estimated completion is 2025-03-05.
What interventions are being tested in trial NCT05570305?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG), Zibotentan (DRUG), Dapagliflozin and Zibotentan (DRUG).
Who is sponsoring clinical trial NCT05570305?
This trial is sponsored by University Medical Center Groningen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.